Antibody Industry Trends

Biointron’s Q2 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June.

Single-domain antibodies (sdAbs), also known as VHH antibodies or nanobodies, are the smallest functional fragments of antibodies, consisting of a single variable domain derived from heavy-chain-only antibodies found in camelids or engineered from human immunoglobulin frameworks. Despite their small

Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d

Antibody-drug conjugates (ADCs) couple the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Recent advances have been reported in both hematologic and solid tumors, with next-generation ADCs overcoming limitations of traditional therapies through improved t

Non–small cell lung cancer(NSCLC) remains the leading cause of cancer-related mortality worldwide. Since 2011, the U.S. Food and Drug Administration has approved over 30 new therapies for advanced NSCLC, primarily tyrosine kinase inhibitors and immune checkpoint inhibitors. Biologic age

The rational design and optimization of therapeutic antibodies is increasingly being improved with high-resolution structural data and machine learning (ML) frameworks that can model complex antibody-antigen interactions. Recent research highlights a movement toward the use of large-scale, curated s

Recent studies highlighttheleveraging of distinct immunological functions of IgE to augment or replace conventional IgG1-based therapies, particularly for treatment-resistant solid tumors. Building on growing evidence of IgE’s pro-inflammatory, tumor-reprogramming capabilities, novel hy

Natural killer (NK) cell-based therapies are rapidly gaining traction as immunotherapies, offering advantages over traditional T cell-based approaches, particularly in safety and specificity. While T cell engagers (TCEs) have demonstrated clinical efficacy, their use is limited by toxicities such as

​Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow, often resulting in anemia, bone lesions, hypercalcemia, and renal dysfunction.

Over the past decade, the Fc domain of antibodies was thought of as a passive structural region appreciated primarily for its interaction with Fcγ receptors (FcγRs) and the neonatal Fc receptor (FcRn). Now, the Fc region is a major focus of innovation, enabling fine-tuned control over immune engag

The fight against Alzheimer’s disease (AD) has entered a new era, driven by major advances in immunotherapy. Monoclonal antibodies (mAbs) targeting hallmark proteins such as amyloid-beta and tau, have dominated recent research, clinical trials, and regulatory approvals. However, while new therapies show potential, the field faces critical questions about efficacy, safety, and scientific validity.

​As antibody-based therapies continue to advance the treatment of cancer, autoimmune diseases, and infectious disorders, a parallel challenge has emerged: managing the immune system’s response to these biologics.